UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 29, 2024 THERAPEUTICSMD, INC. (Exact Name of Registrant as Specified in its Charter) | Nevada | 001-00100 | 87-0233535 | | --- | --- | --- | | (State or Other Jurisdiction | (Commission | (IRS Employer | | of Incorporation) | File Number) | Identification No.) | 951 Yamato Road, Suite 220 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-00100 TherapeuticsMD, INC. (Exact name of Registrant as specified in its Charter) Nevada 87-0233535 (Stat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-00100 THERAPEUTICSMD, INC. (Exact name of Registrant as specified in its Charter) Nevada 87-0233535 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-00100 THERAPEUTICSMD, INC. (Exact name of Registrant as specified in its Charter) Nevada 87-0233535 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-00100 THERAPEUTICSMD, INC. (Exact name of Registrant as specified in its Charter) Nevada 87-0233535 (State or other juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission File Number: 001-00100 THERAPEUTICSMD, INC. (Exact name of Registrant as specified in its Charter) of incorp ...

Financial Performance - The company reported a loss from operations of $45.1 million and interest expense of $26.1 million for the six months ended June 30, 2022[104]. - Total revenue for Q2 2022 was $28.6 million, an increase of $5.6 million, or 24.2%, compared to Q2 2021[119]. - ANNOVERA sales were $18.3 million for Q2 2022, an increase of $8.7 million, or 91.2%, compared to Q2 2021[120]. - IMVEXXY sales were $6.7 million for Q2 2022, a decrease of $3.2 million, or 32.2%, compared to Q2 2021[121]. - BIJUVA sales were $2.7 million for Q2 2022, an increase of $0.5 million, or 23.1%, compared to Q2 2021[122]. - Gross profit for Q2 2022 was $23.8 million, an increase of $5.0 million, or 26.2%, compared to Q2 2021[125]. - Total operating expenses for Q2 2022 were $42.7 million, a decrease of $11.4 million, or 21.1%, compared to Q2 2021[126]. - Net income for Q2 2022 was $112.3 million, or $12.83 per basic common share, including a non-recurring gain of $142.8 million from the vitaCare divestiture[131]. - Total revenue for the first six months of 2022 was $47.9 million, an increase of $5.0 million, or 11.7%, compared to the first six months of 2021[132]. - IMVEXXY sales for the first six months of 2022 were $13.6 million, a decrease of $3.2 million, or 19.1%, compared to the first six months of 2021[133]. - BIJUVA sales for the first six months of 2022 were $5.2 million, an increase of $0.6 million, or 13.3%, compared to the first six months of 2021[134]. - Prescription vitamin sales decreased to $1.8 million for the first six months of 2022, down $1.0 million or 37.1% compared to the same period in 2021[137]. - Total product sales increased to $47.4 million for the first six months of 2022, an increase of $4.8 million or 11.3% compared to the first six months of 2021[137]. - Gross profit for the first six months of 2022 was $38.3 million, an increase of $4.2 million or 12.5% compared to the same period in 2021[139]. - Total operating expenses decreased to $83.4 million for the first six months of 2022, a decrease of $15.1 million or 15.4% compared to the first six months of 2021[140]. - Net income for the first six months of 2022 was $63.3 million, or $7.29 per basic common share, including a non-recurring gain of $142.8 million from the sale of the vitaCare business[146]. Cash Flow and Liquidity - Net cash used in operating activities was $44.9 million for the first six months of 2022, a decrease of $20.0 million or 30.8% compared to the same period in 2021[151]. - Net cash provided by investing activities was $142.3 million for the first six months of 2022, an increase of $142.9 million or 27110.8% compared to the first six months of 2021[152]. - Net cash used in financing activities was $125.0 million for the first six months of 2022, a change of $221.4 million or 229.7% compared to the same period in 2021[153]. - As of June 30, 2022, the company had cash totaling $26.3 million[147]. - The company had $90.8 million in term loans outstanding under its Financing Agreement as of June 30, 2022, down from $200.0 million as of December 31, 2021[157]. Divestiture and Strategic Actions - The company completed the divestiture of vitaCare Prescription Services, receiving net proceeds of $142.6 million and recognizing a gain on sale of $143.4 million[96]. - The company may receive up to an additional $7.0 million in earn-out consideration from the vitaCare divestiture, contingent on vitaCare's financial performance through 2023[96]. - The company has a long-term services agreement with vitaCare to utilize its platform for product support post-divestiture[98]. - The company is pursuing various equity and debt refinancing options to address capital needs, including potential Chapter 11 protection if financing fails[105]. Product Development and Market Conditions - ANNOVERA, a contraceptive product, is expected to meet future demand with increased manufacturing capacity following FDA approval of a supplemental NDA[114]. - The company has implemented significant cost-saving measures in response to the COVID-19 pandemic, including reducing marketing expenses and hiring restrictions[101]. - The company continues to face uncertainties related to the COVID-19 pandemic, which may impact financial condition and liquidity[102]. - The company’s product portfolio includes IMVEXXY, BIJUVA, and ANNOVERA, with ongoing commercialization efforts since their respective launches[111]. Financial Position - Current liabilities exceeded current assets by $65.4 million, and total liabilities exceeded total assets by $26.1 million as of June 30, 2022[104]. - The company qualifies as a "smaller reporting company" under Rule 12b-2 of the Securities Exchange Act of 1934[160]. - The company is not required to provide quantitative and qualitative disclosures about market risk due to its reporting status[160].

TherapeuticsMD, Inc. (NASDAQ:TXMD) Q2 2022 Earnings Conference Call August 15, 2022 8:30 PM ET Company Participants Lisa Wilson - IR Hugh O'Dowd - CEO Michael Donegan - Interim CFO Mark Glickman - Chief Commercial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright Operator [Starts Abruptly] for the TherapeuticsMD Second Quarter 2022 Financial Results Conference Call. Following prepared remarks from the company, we will open the call for questions. I would now like to turn the call over to I ...

TherapeuticsMD® | --- | --- | --- | |-------------------------------------------------------------------------------|-------|-------| | | | | | Building the Premier Women's Health Company Q2 2022 Earnings August 15, 2022 | | | | FOR INVESTOR PRESENTATION PURPOSES ONLY. | | | Forward-Looking Statements This presentation by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD's objectives, plans and s ...

Financial Data and Key Metrics Changes - The company's net product revenue for Q1 2022 was $19.3 million, a slight increase of 3.5% compared to $18.7 million in Q4 2021, but a decrease of 2.7% from $19.9 million in Q1 2021 [8][12] - Gross profit for Q1 2022 was $14.5 million, down 4.7% from Q1 2021, but up 3.8% from Q4 2021 [18] - Selling and marketing costs decreased by 21.3% year-over-year to $18.9 million, and general and administrative costs increased by 11% to $20.4 million compared to Q1 2021 [19][20] Business Line Data and Key Metrics Changes - ANNOVERA sales were $8.5 million in Q1 2022, down 2.7% from Q1 2021, but up 8.7% from Q4 2021 [13][14] - IMVEXXY net revenue remained flat at $7 million compared to Q1 2021, but increased by 4.5% from Q4 2021 [14] - BIJUVA sales increased by 4.7% year-over-year to $2.6 million, but decreased by 4.5% quarter-over-quarter [15] Market Data and Key Metrics Changes - Total quarterly prescriptions for ANNOVERA increased by 27% compared to Q1 2021, despite supply challenges [29] - The company is seeing early improvements in demand for IMVEXXY and BIJUVA following strategic realignments [30][32] Company Strategy and Development Direction - The company is focused on optimizing sales targeting and leveraging all three product assets effectively [26] - There is an emphasis on building inventory for ANNOVERA to meet growing demand, with expectations of improved manufacturing in Q2 2022 [28][29] - The management believes that the new commercial plan is yielding positive results, with increased sales productivity and robust demand for products [33] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that ANNOVERA supply challenges peaked in Q1 2022 and expects incremental improvement as the year progresses [8] - The company has paused offering full-year guidance for 2022 until clarity on capital structure and FDA feedback is received [9] Other Important Information - The company completed the $150 million divestiture of vitaCare, receiving approximately $138.5 million in cash [11] - Net cash used in operating activities was $29.5 million for Q1 2022, with $30.4 million in cash as of March 31, 2022 [25] Q&A Session Summary Question: What are the expectations for ANNOVERA's supply challenges? - Management believes that supply challenges peaked in Q1 2022 and anticipates improvements in manufacturing throughout Q2 [8][29] Question: How is the company addressing sales productivity? - The company is focusing on optimizing sales targeting and leveraging all three product assets effectively, which has already shown positive results [26][33]